Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated Share Price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:30:00 07/12/2024 am IST 		5-day change 1st Jan Change
462.10 USD +0.47% Intraday chart for Vertex Pharmaceuticals Incorporated -1.29% +13.57%
22/11 Wolfe Research Raises Price Target on Vertex Pharmaceuticals to $538 From $518, Maintains Outperform Rating MT
21/11 New entry in MarketScreener's USA portfolio Our Logo

Valuation: Vertex Pharmaceuticals Incorporated

Capitalization 12TCr 11TCr 10TCr 9.34TCr 17TCr 10,07800Cr 19TCr 1,29900Cr 48TCr 4,14100Cr 45TCr 44TCr 17,84200Cr P/E ratio 2024 *
-260x
P/E ratio 2025 * 27.6x
Enterprise value 11TCr 10TCr 9.63TCr 8.61TCr 16TCr 9,29600Cr 17TCr 1,19800Cr 44TCr 3,81900Cr 41TCr 40TCr 16,45600Cr EV / Sales 2024 *
10.1x
EV / Sales 2025 * 8.88x
Free-Float
99.92%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Vertex Pharmaceuticals Incorporated

Dynamic Chart

Latest news: Vertex Pharmaceuticals Incorporated

Wolfe Research Raises Price Target on Vertex Pharmaceuticals to $538 From $518, Maintains Outperform Rating 22/11 MT
New entry in MarketScreener's USA portfolio 21/11Our Logo
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560 21/11 MT
Vertex Pharmaceuticals Incorporated Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 08:00 AM 19/11
Vertex Pharmaceuticals Incorporated Presents at Guggenheim Securities Inaugural Healthcare Innovation Conference, Nov-12-2024 09:00 AM 12/11
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530 07/11 MT
Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on February 7, 2023. 06/11 CI
Sector Update: Health Care Stocks Rise Tuesday Afternoon 06/11 MT
Top Midday Stories: Boeing Workers Approve Labor Contract, End Strike; Palantir Raises FY Revenue Guidance 05/11 MT
UBS Raises Price Target on Vertex Pharmaceuticals to $586 From $562, Maintains Buy Rating 05/11 MT
Global markets live: Palantir soars, Boeing strike ends 05/11Our Logo
RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $451 From $437, Maintains Sector Perform Rating 05/11 MT
The Election Effect 05/11Our Logo
More news

Last Transcript: Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 08:00 AM
19/11
More transcripts

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

Wolfe Research Raises Price Target on Vertex Pharmaceuticals to $538 From $518, Maintains Outperform Rating 22/11 MT
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560 21/11 MT
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530 07/11 MT
UBS Raises Price Target on Vertex Pharmaceuticals to $586 From $562, Maintains Buy Rating 05/11 MT
RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $451 From $437, Maintains Sector Perform Rating 05/11 MT
More recommendations

Press Releases: Vertex Pharmaceuticals Incorporated

Vertex: Q3 Earnings Snapshot 05/11 AQ
Vertex Reports Third Quarter 2024 Financial Results 05/11 BU
Vertex to Participate in Upcoming November Investor Conferences 30/10 BU
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology Annual Kidney Week Congress 28/10 AQ
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress 25/10 BU
More press releases

News in other languages: Vertex Pharmaceuticals Incorporated

Nuovo acquisto nel portafoglio USA 22/11
Neuzugang im USA-Portfolio 22/11
Últimas compras en la Cartera Estadounidense 22/11
Nieuwe aankoop voor de VS-portefeuille 22/11
Nouvel achat dans le portefeuille Investisseur USA 21/11
More news

Quotes and Performance

1 day+0.47%
1 week-1.29%
Current month-1.29%
1 month-6.39%
3 months-1.26%
6 months-4.83%
Current year+13.57%
More quotes

Course Extremes

1 week
450.00
Extreme 450
468.51
1 month
445.00
Extreme 445
519.88
Current year
391.01
Extreme 391.01
519.88
1 year
348.46
Extreme 348.46
519.88
3 years
203.73
Extreme 203.73
519.88
5 years
176.36
Extreme 176.36
519.88
10 years
71.46
Extreme 71.46
519.88
More quotes

Managers and Directors: Vertex Pharmaceuticals Incorporated

Director TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 01/04/2020
Charles Wagner DFI
 Director of Finance/CFO 56 10/04/2019
Mike Tirozzi CTO
 Chief Tech/Sci/R&D Officer - 01/01/2019
Manager TitleAgeSince
Bruce Sachs BRD
 Director/Board Member 64 01/01/1998
Jeffrey Leiden CHM
 Chairman 68 01/05/2012
Sangeeta Bhatia BRD
 Director/Board Member 55 18/06/2015
More insiders

ETFs: Vertex Pharmaceuticals Incorporated

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.67% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.08% 0 M€ 0.00% -
More ETFs: Vertex Pharmaceuticals Incorporated

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+0.47%-1.29%+30.74%+125.35%12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.32%+3.70%-6.91%+24.48%8.37TCr
ARGENX SE Stock argenx SE
-0.20%+0.75%+38.36%+136.98%3.77TCr
BIONTECH SE Stock BioNTech SE
+2.42%+2.81%+20.11%-56.50%2.92TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
+1.96%-4.36%+13.00%-31.28%2.18TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+7.41%+10.13%-27.49%-59.61%2.17TCr
GENMAB A/S Stock Genmab A/S
-0.16%+1.51%-30.38%-36.15%1.45TCr
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
+5.82%+0.43%+662.96%+268.59%1.37TCr
INSMED INCORPORATED Stock Insmed Incorporated
+0.09%+0.32%+176.49%+181.24%1.35TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.36%+1.10%+7.26%+58.81%1.3TCr
Average +2.05%+1.08%+88.41%+61.19% 3.68TCr
Weighted average by Cap. +1.44%+0.60%+43.22%+67.58%
See all sector performances

Financials

2024 *2025 *
Net sales 1.09TCr 1.03TCr 954.49Cr 853.62Cr 1.54TCr 92TCr 1.7TCr 12TCr 4.39TCr 38TCr 4.09TCr 4TCr 1,63100Cr 1.18TCr 1.12TCr 1.04TCr 926.68Cr 1.67TCr 1,00000Cr 1.85TCr 13TCr 4.77TCr 41TCr 4.44TCr 4.34TCr 1,77100Cr
Net income -46Cr -44Cr -41Cr -36Cr -66Cr -3.94TCr -73Cr -507.51Cr -187.62Cr -1.62TCr -174.66Cr -170.78Cr -6.97TCr 428.18Cr 405.18Cr 375.61Cr 335.91Cr 605.37Cr 36TCr 670.14Cr 4.67TCr 1.73TCr 15TCr 1.61TCr 1.57TCr 64TCr
Net Debt -924Cr -874.38Cr -810.56Cr -724.9Cr -1.31TCr -78TCr -1.45TCr -10TCr -3.73TCr -32TCr -3.47TCr -3.39TCr -1,38500Cr -1.41TCr -1.34TCr -1.24TCr -1.11TCr -1.99TCr -1,19500Cr -2.21TCr -15TCr -5.69TCr -49TCr -5.3TCr -5.18TCr -2,11500Cr
More financial data * Estimated data

Company Profile

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Employees
5,400
Sector
Biotechnology & Medical Research
Calendar
11/02/2025 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
06/24/06 462.10 $ +0.47% 1,115,377
05/24/05 459.92 $ -0.88% 1,183,850
04/24/04 463.98 $ +1.53% 1,220,618
03/24/03 456.97 $ -1.88% 1,181,804
02/24/02 465.73 $ -0.51% 960,021

Delayed Quote Nasdaq, December 07, 2024 at 02:30 am IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart VERTEX-PHARMACEUTICALS-IN More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart VERTEX-PHARMACEUTICALS-INMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
462.10USD
Average target price
513.52USD
Spread / Average Target
+11.13%
Consensus
Profit revisions
estimates-change-chart VERTEX-PHARMACEUTICALS-IN Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart VERTEX-PHARMACEUTICALS-IN Company calendar
  1. Stock Market
  2. Equities
  3. VRTX Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition